Skip to main content
Clinical Trials/NL-OMON54821
NL-OMON54821
Completed
Phase 2

A Phase 2, Multicenter, Blinded, Sham Procedure-Controlled Trial of Renal Denervation by the Peregrine System Kit, in Subjects with Hypertension, in the Absence of Antihypertensive Medications - The TARGET BP OFF-MED Trial

Ablative Solutions Inc0 sites50 target enrollmentStarted: TBDLast updated:

Overview

Phase
Phase 2
Status
Completed
Enrollment
50

Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 to 99 (—)

Inclusion Criteria

  • 1\. Subject has provided written informed consent.
  • 2\. Male or female subject, aged \>\=18 and \<\=80 years at time of enrollment.
  • 3\. If subject has a documented history of uncontrolled hypertension (see
  • definition in Definition of
  • Terms section of protocol) and is currently taking no (0\)
  • antihypertensive medications, he/she
  • o Have 3 office blood pressure measurements with a mean office SBP of \>\=140 mmHg
  • and \<\=180
  • mmHg AND mean office DBP \>\=90 mmHg, and
  • o Be willing to adhere to the no\-medication regimen for at least 12 weeks (4

Exclusion Criteria

  • 1\. Subject has a contraindication known for conventional percutaneous
  • interventional procedures.
  • 2\. Subject has an acute or sub\-acute infection that the investigator judges
  • would pose unacceptable procedural risks to the subject.
  • 3\. Subject has imaging\-assessed renal artery anatomy abnormalities or
  • variations based on investigator's evaluation of the screening images (i.e.
  • MRA/CTA examination and/or renal angiography) meeting one of the following
  • o Main renal artery that has a diameter of \<4 mm or \>7 mm and length of \<5 mm
  • o Accessory renal arteries with diameter \>2 mm or \<4 mm, which supply \>20% of
  • the whole kidney parenchyma on that side, per the investigator's judgment.

Investigators

Similar Trials

Active, not recruiting
Phase 1
Study of the Effect of Kidney Denervation on Blood Pressure in Subjects with High Blood Pressure Without MedicatioHypertensionMedDRA version: 20.0Level: PTClassification code 10020772Term: HypertensionSystem Organ Class: 10047065 - Vascular disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
EUCTR2018-000036-96-DEAblative Solutions, Inc.400
Active, not recruiting
Phase 1
Study of the Effect of Kidney Denervation on Blood Pressure in Subjects with High Blood Pressure Without MedicatioHypertensionMedDRA version: 20.0Level: PTClassification code 10020772Term: HypertensionSystem Organ Class: 10047065 - Vascular disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
EUCTR2018-000036-96-GBAblative Solutions, Inc.400
Active, not recruiting
Phase 1
Study of the Effect of Kidney Denervation on Blood Pressure in Subjects with High Blood Pressure Without MedicatioHypertensionMedDRA version: 20.0Level: PTClassification code 10020772Term: HypertensionSystem Organ Class: 10047065 - Vascular disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
EUCTR2018-000036-96-NLAblative Solutions, Inc.400
Active, not recruiting
Phase 1
Study of the Effect of Kidney Denervation on Blood Pressure in Subjects with High Blood Pressure Without MedicatioHypertensionMedDRA version: 20.0Level: PTClassification code 10020772Term: HypertensionSystem Organ Class: 10047065 - Vascular disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
EUCTR2018-000036-96-IEAblative Solutions, Inc.400
Active, not recruiting
Phase 1
Study of the Effect of Kidney Denervation on Blood Pressure in Subjects with High Blood Pressure Without MedicatioHypertensionMedDRA version: 20.0Level: PTClassification code 10020772Term: HypertensionSystem Organ Class: 10047065 - Vascular disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
EUCTR2018-000036-96-BEAblative Solutions, Inc.400